(Q37024077)

17 August 2017

1 reference

title

Endothelin receptor antagonists in cancer therapy (English)

1 reference

17 August 2017

3

George Wilding

1 reference

17 August 2017

Mihailo Lalich

1

1 reference

17 August 2017

Douglas G McNeel

series ordinal

2

1 reference

17 August 2017

Glenn Liu

series ordinal

4

1 reference

17 August 2017

1 December 2007

1 reference

17 August 2017

1 reference

17 August 2017

25

1 reference

17 August 2017

785-794

1 reference

17 August 2017

8

1 reference

Endothelins in health and disease: an overview

17 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

The endothelin axis: emerging role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Endothelin receptor antagonists in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Endothelin Inhibition: Novel Therapy for Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Growth regulatory properties of endothelins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Enhanced endothelin ET(B) receptor down-regulation in human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Osteoblasts in prostate cancer metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Factors regulating the growth of metastatic cancer in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Endothelin-1 and osteoblastic metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Endothelin expression and responsiveness in human ovarian carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Paracrine regulation of ovarian cancer by endothelin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Role of endothelin-1 in neovascularization of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Endothelin-1 promotes proteolytic activity of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Clinical trial design for target specific anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Positron emission tomography (PET): Expanding the horizons of oncology drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522588

10.1080/07357900701522588

21 January 2018

Identifiers

DOI

1 reference

release_krq73wecnjcu5gzm3a5eppoina

17 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/krq73wecnjcu5gzm3a5eppoina

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference